Fertin Sustainability Profile
Fertin, officially known as Fertin Pharma A/S, is a leading player in the pharmaceutical and healthcare industry, headquartered in Denmark (DK). Founded in 2006, the company has established itself as a pioneer in the development of innovative oral delivery systems, particularly in the field of nicotine replacement therapy and other consumer health products. With a strong presence in Europe and North America, Fertin focuses on creating unique solutions that enhance the efficacy and user experience of medicinal products. Their core offerings include advanced chewing gum and lozenge formulations, which are distinguished by their high bioavailability and consumer-friendly designs. Fertin's commitment to quality and innovation has positioned it as a trusted partner for global brands, earning recognition for its contributions to the industry and its ability to adapt to evolving market demands.
DitchCarbon Score
How does Fertin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fertin's score of 68 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fertin's reported carbon emissions
In 2024, Fertin Pharma A/S reported total carbon emissions of approximately 36,673,000 kg CO2e across all scopes. This includes 3,654,000 kg CO2e from Scope 1, 1,538,000 kg CO2e from Scope 2 (market-based), and a significant 36,673,000 kg CO2e from Scope 3 emissions. The total emissions from Scope 1 and 2 combined (market-based) amounted to about 5,192,000 kg CO2e. Comparatively, in 2023, Fertin's emissions were approximately 34,261,000 kg CO2e, with Scope 1 emissions at 4,742,000 kg CO2e and Scope 2 emissions (market-based) at 1,865,000 kg CO2e. This indicates a slight increase in overall emissions year-on-year. Fertin Pharma's emissions data is cascaded from its parent company, Philip Morris International Inc., reflecting a corporate family relationship. However, there are currently no specific reduction targets or climate pledges disclosed by Fertin, nor are there any initiatives reported under the Science Based Targets initiative (SBTi) or other climate frameworks. Overall, Fertin Pharma A/S is committed to addressing its carbon footprint, but further details on specific reduction strategies or targets are not available at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | - | - | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
How Carbon Intensive is Fertin's Industry?
How Carbon Intensive is Fertin's Location?
Fertin's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Fertin has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
